ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer (ADELE): a randomised phase 2 trial
The ADELE clinical trial seeks to improve outcomes for people with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy & radiotherapy. It is hoped that this study may improve relapse rates in high-risk endometrial cancer by adding Tislelizumab immunotherapy to standard treatment.
Primary Sponsor
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
135
Expected Date of Accrual
March 2025
Trial Chairperson
Professor Linda Mileshkin, Peter MacCallum Cancer Centre, VIC, Australia
Dr Yeh Chen Lee, NHMRC Clinical Trials Centre & Prince of Wales Hospital
Trial Contact
qa@trog.com.au
Related Post
Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer
LATEST NEWS: 11 JUNE 2025 New findings from a
MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer
LATEST NEWS: 10 JUNE 2025 A trial of a
